Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases.
Br J Haematol
; 204(3): 931-938, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38115798
3.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
4.
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299578
5.
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Haematologica
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546696
6.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269857
7.
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 24(7): e293-e311, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414019
8.
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.
Eur J Haematol
; 111(2): 181-190, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37082839
9.
Werner helicase is required for proliferation and DNA damage repair in multiple myeloma.
Mol Biol Rep
; 50(2): 1565-1573, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36515823
10.
Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation.
J Clin Apher
; 38(6): 685-693, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37503703
11.
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
J Oncol Pharm Pract
; 29(5): 1172-1177, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36067063
12.
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Lancet Oncol
; 23(1): 65-76, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34871550
13.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Lancet Oncol
; 23(3): 416-427, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35151415
14.
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.
Br J Haematol
; 197(1): 82-96, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35166376
15.
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Blood
; 136(26): 3033-3040, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33367546
16.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol
; 108(1): 73-83, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496096
17.
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Am J Hematol
; 97(4): 481-490, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35089607
18.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
19.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(6): 801-812, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34087126
20.
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Lancet Oncol
; 22(1): 142-154, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33301738